1
|
Wang D, Sun Y, Li W, Ye F, Zhang Y, Guo Y, Zhang DY, Suo J. Antiproliferative effects of the CDK6 inhibitor PD0332991 and its effect on signaling networks in gastric cancer cells. Int J Mol Med 2018; 41:2473-2484. [PMID: 29436583 PMCID: PMC5846637 DOI: 10.3892/ijmm.2018.3460] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2016] [Accepted: 12/20/2017] [Indexed: 12/31/2022] Open
Abstract
PD0332991 (palbociclib/Ibrance®) is a cyclin-dependent kinase (CDK)4/6 inhibitor that has recently been approved for the treatment of estrogen receptor-positive advanced breast cancer. The present study investigated the antiproliferative effects of PD0332991 on gastric cancer (GC) cells and the underlying molecular mechanisms. The activity of PD0332991 was tested in several GC cell lines, including AGS, KATO-III, NCI-N87 and HS746T. Growth inhibitory activity of PD0332991, alone or in combination with fluorouracil (5-FU), was measured by MTT assay. The effects of PD0332991 on cell cycle progression were analyzed by flow cytometry and western blotting. Protein pathway array and Ingenuity Pathway Analysis were used to identify signaling pathways that may mediate the antiproliferative effects of PD0332991. PD0332991 inhibited proliferation in a dose-dependent manner and enhanced the activity of 5-FU in all GC cell lines tested. Cells treated with PD0332991 exhibited cell cycle arrest in G1 phase of the cell cycle, whereas the number of cells in G2/M phase was decreased. PD0332991 also inhibited CDK6-specific phosphorylation of retinoblastoma on Ser780, reduced the expression of cyclin D1, and induced expression of p53 and p27. Furthermore, 31 proteins were identified, the expression of which was significantly altered following treatment with PD0332991 in at least three cell lines. Pathway analysis indicated that the altered proteins were frequently associated with cell death, cell cycle and the molecular mechanism of cancer. The results of the present study indicated that PD0332991 may inhibit cell proliferation via modulation of the cell cycle, and may affect numerous oncogenic signaling pathways. Therefore, PD0332991 may be considered effective for the treatment of GC.
Collapse
Affiliation(s)
- Daguang Wang
- Department of Gastric and Colorectal Surgery, The First Hospital, Jilin University, Changchun, Jilin 130021, P.R. China
| | - Yabin Sun
- Department of Ophthalmology, The First Hospital, Jilin University, Changchun, Jilin 130021, P.R. China
| | - Wei Li
- Department of Gastric and Colorectal Surgery, The First Hospital, Jilin University, Changchun, Jilin 130021, P.R. China
| | - Fei Ye
- Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Yang Zhang
- Department of Gastric and Colorectal Surgery, The First Hospital, Jilin University, Changchun, Jilin 130021, P.R. China
| | - Yuchen Guo
- Department of Gastric and Colorectal Surgery, The First Hospital, Jilin University, Changchun, Jilin 130021, P.R. China
| | - David Y Zhang
- Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA
| | - Jian Suo
- Department of Gastric and Colorectal Surgery, The First Hospital, Jilin University, Changchun, Jilin 130021, P.R. China
| |
Collapse
|
2
|
Tian F, Wei H, Tian H, Qiu Y, Xu J. miR-33a is downregulated in melanoma cells and modulates cell proliferation by targeting PCTAIRE1. Oncol Lett 2016; 11:2741-2746. [PMID: 27073545 PMCID: PMC4812543 DOI: 10.3892/ol.2016.4321] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2015] [Accepted: 01/26/2016] [Indexed: 02/06/2023] Open
Abstract
MicroRNA-33a (miR-33a) was previously identified as a lipid regulator that controls the cellular balance between cholesterol and fatty acid metabolism. However, its role in tumor progression is largely unknown. The present study identified that miR-33a acts as a tumor suppressor in melanoma cells. The present study revealed that miR-33a was downregulated in melanoma cells compared with melanocytes. Overexpression of miR-33a suppressed the colony formation of human melanoma SK-MEL-1 and WM-115 cells. Furthermore, a bromodeoxyuridine incorporation assay and anaphase analysis revealed that miR-33a inhibits melanoma cell proliferation. miR-33a overexpression inhibited p27 phosphorylation and upregulated p27 expression. Additionally, the present study demonstrated that PCTAIRE1 was a direct target of miR-33a; miR-33a overexpression suppressed the luciferase activity of a reporter construct containing a 3′-untranslated region of PCTAIRE1 and downregulated PCTAIRE1 in melanoma cells. An overexpression of PCTAIRE1 reversed the miR-33a-induced p27 accumulation and tumor suppressive effects. In summary, the present findings offer novel mechanistic insights into miR-33a and its downstream target in melanoma cells.
Collapse
Affiliation(s)
- Fangzhen Tian
- Department of Dermatology, Jining No. 1 People's Hospital, Jining, Shandong 272000, P.R. China
| | - Hongtu Wei
- Department of Orthopedics, Jining No. 1 People's Hospital, Jining, Shandong 272000, P.R. China
| | - Hua Tian
- Department of Public Health, Jining Beihu Hospital, Jining, Shandong 272067, P.R. China
| | - Ying Qiu
- Department of Dermatology, Jining No. 1 People's Hospital, Jining, Shandong 272000, P.R. China
| | - Jian Xu
- Department of Public Health, Center for Disease Control and Prevention of Jining City, Jining, Shandong 272113, P.R. China
| |
Collapse
|